Search

Cutaneous allodynia (CA) is a frequent complaint during migraine attacks, recently associated with migraine transformation as well as psychiatric comorbidities. The aim of our study was to define the clinical features of allodynic migraineurs, in particular, the relationship between CA and personality profile. Between October 2008 and December 2009, 410 migraineurs admitted for the first time to our Headache Center underwent Allodynia Symptom Checklist, MIgraine DIsability Assessment Scale (MIDAS) and psychometric tests [Tridimensional Personality Questionnaire (TPQ), Toronto Alexithymia Scale, State and Trait Anxiety Inventory (STAI Y 1-2), and Beck Depression Inventory (BDI)]. Allodynia was present in 63% of cases, mostly in females. In CA patients, an association with female sex, chronic migraine, higher values of MIDAS, BDI, harm avoidance (HA, a TPQ dimension) and STAI Y-2 was found. Interestingly, CA appears to be associated with depression and a particular personality profile characterized by higher values of HA, suggesting an involvement of the serotonergic system in the development of CA in migraine. In conclusion, CA is associated with progression of migraine and it could be a marker of psychiatric comorbidities, in particular, depression and anxious trait. [ABSTRACT FROM AUTHOR]

To evaluate the influence of psychometric variables on the 'repeater' phenomenon in an emergency department, 15 'repeaters' and 27 outpatient migraineurs were recruited. All patients were submitted to the Beck Depression Inventory (BDI), State and Trait Anxiety Inventory, Toronto Alexithymia Scale-20 (TAS-20), Tridimensional Personality Questionnaire and Migraine DIsability Assessment Scale (MIDAS). The 'repeater' group showed higher MIDAS total scores (p=0.02) and higher scores in TAS-20 (p=0.02) than the outpatients. A higher frequency of alexithymic trait (p=0.02) and higher BDI scores (p=0.07) have also been observed in the 'repeater' group than the outpatients. Alexithymia and depressive mood associated with high disability may be a specific psychosocial pattern of 'repeater' migraineurs. The psychometric evaluation of this population may be important to explain the 'repeaters' phenomenon. [ABSTRACT FROM AUTHOR]

Serum prolactin is increased during chronic flunarizine treatment of patients suffering from migraine. In order to clarify the role of calcium in control of the secretion of anterior pituitary hormones, a study has now been made of the effects of chronic nimodipine and propranolol treatment of migraine patients on prolactin (PRL), luteinizing hormone (LH) and growth hormone (GH) levels. 11 patients were treated with nimodipine and 8 with propranolol for four months. A statistically significant reduction in the frequency of the attacks was demonstrated in both groups. No significant change was found in the hormones levels during nimodipine treatment. [ABSTRACT FROM AUTHOR]

Copyright of Italian Journal of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Migraine is one of the most common neurological diseases afflicting 12% of general population but is poorly recognized and largely untreated. Migraine is a disabling disease with very high social costs as it affects young individuals during their productive age. Quality of life in migraineurs is impaired. Furthermore, the economic burden of migraine, usually evaluated in terms of direct and indirect costs, is relevant and could be reduced by an early diagnosis and an appropriate treatment. [ABSTRACT FROM AUTHOR]

Reports on pharmacologic treatment for cluster headache (CH) which can be abortive or acute, prophylactic or preventive, or a combination of the two. Shortening of the bouts of episodic cluster and controlling of the frequency of attacks in both the episodic and chronic forms; Effectiveness of the first drug called dihydroergotamine before sumatriptan.